217 related articles for article (PubMed ID: 25151299)
1. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study.
Tenori L; Oakman C; Morris PG; Gralka E; Turner N; Cappadona S; Fornier M; Hudis C; Norton L; Luchinat C; Di Leo A
Mol Oncol; 2015 Jan; 9(1):128-39. PubMed ID: 25151299
[TBL] [Abstract][Full Text] [Related]
2. Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Hart CD; Vignoli A; Tenori L; Uy GL; Van To T; Adebamowo C; Hossain SM; Biganzoli L; Risi E; Love RR; Luchinat C; Di Leo A
Clin Cancer Res; 2017 Mar; 23(6):1422-1431. PubMed ID: 28082280
[No Abstract] [Full Text] [Related]
3. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.
Oakman C; Tenori L; Claudino WM; Cappadona S; Nepi S; Battaglia A; Bernini P; Zafarana E; Saccenti E; Fornier M; Morris PG; Biganzoli L; Luchinat C; Bertini I; Di Leo A
Ann Oncol; 2011 Jun; 22(6):1295-1301. PubMed ID: 21199886
[TBL] [Abstract][Full Text] [Related]
4. A plasma metabolomic signature discloses human breast cancer.
Jové M; Collado R; Quiles JL; Ramírez-Tortosa MC; Sol J; Ruiz-Sanjuan M; Fernandez M; de la Torre Cabrera C; Ramírez-Tortosa C; Granados-Principal S; Sánchez-Rovira P; Pamplona R
Oncotarget; 2017 Mar; 8(12):19522-19533. PubMed ID: 28076849
[TBL] [Abstract][Full Text] [Related]
5. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Tenori L; Oakman C; Claudino WM; Bernini P; Cappadona S; Nepi S; Biganzoli L; Arbushites MC; Luchinat C; Bertini I; Di Leo A
Mol Oncol; 2012 Aug; 6(4):437-44. PubMed ID: 22687601
[TBL] [Abstract][Full Text] [Related]
6. Early detection of recurrent breast cancer using metabolite profiling.
Asiago VM; Alvarado LZ; Shanaiah N; Gowda GA; Owusu-Sarfo K; Ballas RA; Raftery D
Cancer Res; 2010 Nov; 70(21):8309-18. PubMed ID: 20959483
[TBL] [Abstract][Full Text] [Related]
7. A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.
Di Donato S; Vignoli A; Biagioni C; Malorni L; Mori E; Tenori L; Calamai V; Parnofiello A; Di Pierro G; Migliaccio I; Cantafio S; Baraghini M; Mottino G; Becheri D; Del Monte F; Miceli E; McCartney A; Di Leo A; Luchinat C; Biganzoli L
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199435
[TBL] [Abstract][Full Text] [Related]
8. Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
Yang PJ; Tsai EM; Hou MF; Lee YJ; Wang TN
Breast Cancer; 2024 Jul; 31(4):659-670. PubMed ID: 38652345
[TBL] [Abstract][Full Text] [Related]
9. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
10. Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer.
Fan Y; Zhou X; Xia TS; Chen Z; Li J; Liu Q; Alolga RN; Chen Y; Lai MD; Li P; Zhu W; Qi LW
Oncotarget; 2016 Mar; 7(9):9925-38. PubMed ID: 26848530
[TBL] [Abstract][Full Text] [Related]
11. NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort.
Vignoli A; Tenori L; Giusti B; Takis PG; Valente S; Carrabba N; Balzi D; Barchielli A; Marchionni N; Gensini GF; Marcucci R; Luchinat C; Gori AM
BMC Med; 2019 Jan; 17(1):3. PubMed ID: 30616610
[TBL] [Abstract][Full Text] [Related]
12. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
13. Metabolic fingerprinting in breast cancer stages through
Suman S; Sharma RK; Kumar V; Sinha N; Shukla Y
J Pharm Biomed Anal; 2018 Oct; 160():38-45. PubMed ID: 30059813
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
15. NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer.
Lécuyer L; Victor Bala A; Deschasaux M; Bouchemal N; Nawfal Triba M; Vasson MP; Rossary A; Demidem A; Galan P; Hercberg S; Partula V; Le Moyec L; Srour B; Fiolet T; Latino-Martel P; Kesse-Guyot E; Savarin P; Touvier M
Int J Epidemiol; 2018 Apr; 47(2):484-494. PubMed ID: 29365091
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
17. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.
Jobard E; Pontoizeau C; Blaise BJ; Bachelot T; Elena-Herrmann B; Trédan O
Cancer Lett; 2014 Feb; 343(1):33-41. PubMed ID: 24041867
[TBL] [Abstract][Full Text] [Related]
18. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
19. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
Ogiya A; Yamazaki K; Horii R; Shien T; Horimoto Y; Masuda N; Inao T; Hosoda M; Ishida N; Osako T; Takahashi M; Endo Y; Miyoshi Y; Yasojima H; Tomioka N; Yamashita H;
Breast Cancer; 2017 May; 24(3):473-482. PubMed ID: 27628678
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
